systematic review | Q1504425 |
review article | Q7318358 |
scholarly article | Q13442814 |
P819 | ADS bibcode | 2016PLoSO..1156489G |
P356 | DOI | 10.1371/JOURNAL.PONE.0156489 |
P932 | PMC publication ID | 4934683 |
P698 | PubMed publication ID | 27383192 |
P50 | author | Garrett Green | Q87831239 |
P2093 | author name string | Loren K Mell | |
Ruben Carmona | |||
Kaveh Zakeri | |||
Andrew Sharabi | |||
Chih-Han Lee | |||
Saif Borgan | |||
Zaid Marhoon | |||
P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 |
Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
Two-sided confidence intervals for the single proportion: comparison of seven methods | Q28271313 | ||
Publication bias in clinical research | Q29541186 | ||
A note on competing risks in survival data analysis | Q30951799 | ||
Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns | Q36851212 | ||
Survival end point reporting in randomized cancer clinical trials: a review of major journals | Q37231288 | ||
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. | Q37411227 | ||
Gene-expression-based prognostic assays for breast cancer | Q37741797 | ||
Cancer biomarkers: selecting the right drug for the right patient | Q37982927 | ||
Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review | Q38016057 | ||
Cancer gene expression signatures - the rise and fall? | Q38090088 | ||
Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794. | Q41975833 | ||
Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: a population-based study | Q43489980 | ||
Validated competing event model for the stage I-II endometrial cancer population | Q43733348 | ||
On lumping, splitting, and the nosology of clinical trial populations and end points. | Q45949036 | ||
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? | Q51912002 | ||
More on Cetuximab in Head and Neck Cancer | Q56775178 | ||
Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks | Q62071396 | ||
Reporting recommendations for tumor marker prognostic studies | Q81236405 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neoplasm | Q1216998 |
tumor biomarker | Q66205818 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | e0156489 | |
P577 | publication date | 2016-07-06 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review | |
P478 | volume | 11 |
Search more.